DFTX

Definium Therapeutics Inc

Apr 08 • 04:00PM ET

21.02

+0.44 2.14 %

Healthcare • Biotechnology • USA • NASD

Apr 01, 2:01 PMGAD prevalence study publication drives Definium Therapeutics 8% surge to new 52-week high.

Peers: ATAI HELP CMPS GHRS RLAY RLMD PLRX VTGN FBRX

| Held by: IWM VXF IBB IWN SCHA VTWO XPH IHE IWO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.07	Insider Own	5.36%	Shs Outstand	98.78M	Perf Week	11.22%
Market Cap	2.10B	Forward P/E	-	EPS next Y	-1.82	Insider Trans	-1.58%	Shs Float	94.36M	Perf Month	14.55%
Enterprise Value	1.72B	PEG	-	EPS next Q	-0.48	Inst Own	66.35%	Short Float	15.91%	Perf Quarter	55.59%
Income	-183.79M	P/S	-	EPS this Y	5.62%	Inst Trans	30.39%	Short Ratio	8.33	Perf Half Y	72.01%
Sales	0.00M	P/B	6.25	EPS next Y	6.19%	ROA	-49.52%	Short Interest	15.01M	Perf YTD	56.98%
Book/sh	3.36	P/C	5.09	EPS next 5Y	35.97%	ROE	-64.06%	52W High	21.09 -0.36%	Perf Year	329.86%
Cash/sh	4.13	P/FCF	-	EPS past 3/5Y	-3.78% -1.48%	ROIC	-49.29%	52W Low	4.70 347.23%	Perf 3Y	617.41%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.24% 5.63%	Perf 5Y	-46.31%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-14.47%	Oper. Margin	-	ATR (14)	1.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.29	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	66.71	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	6.29	EPS Q/Q	-23.36%	SMA20	11.61%	Beta	2.45	Target Price	35.23
Payout	-	Debt/Eq	0.12	Sales Q/Q	-	SMA50	17.28%	Rel Volume	0.70	Prev Close	20.58
Employees	106	LT Debt/Eq	0.12	Earnings	Feb 26 AMC	SMA200	63.72%	Avg Volume	1.80M	Price	21.02
IPO	Nov 15, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.44% -	Trades		Volume	1,263,483	Change	2.14%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-26	Initiated	Wolfe Research	Outperform	$25
Jan-30-26	Initiated	Jefferies	Buy	$30
Oct-13-25	Initiated	Needham	Buy	$28
Aug-04-25	Resumed	Oppenheimer	Outperform	$25
Jan-28-25	Initiated	Evercore ISI	Outperform	$23
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$20
Oct-14-24	Resumed	Leerink Partners	Outperform	$20
Jul-24-24	Initiated	ROTH MKM	Buy	$36
May-29-24	Initiated	Robert W. Baird	Outperform	$27
Apr-15-24	Initiated	Leerink Partners	Outperform	$20
Dec-05-23	Initiated	Canaccord Genuity	Buy	$9
Dec-09-22	Resumed	ROTH Capital	Buy	$25
Nov-16-22	Initiated	RBC Capital Mkts	Outperform	$5
Aug-26-22	Initiated	Oppenheimer	Outperform	$3.50
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight	$3
May-04-22	Initiated	ROTH Capital	Buy	$7
Jun-28-21	Initiated	Maxim Group	Buy	$6

Show Previous Ratings

Apr-06-26 09:08AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-26-26 07:00AM	Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 (Business Wire)
Mar-09-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
11:44AM	Loading…
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
12:06AM	Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Feb-26-26 11:13PM	Definium Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates (Business Wire)
Feb-24-26 07:01AM	Definium Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Feb-19-26 04:01PM	Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 (Business Wire)
Feb-18-26 09:32PM	Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III (Insider Monkey)
04:25AM	Psychedelics stocks rise as Compass psilocybin drug heads to FDA (BioPharma Dive)
Feb-02-26 04:00PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire) +8.00%
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Loading…
Jan-29-26 07:00AM	Definium Therapeutics Appoints Roger Adsett to Board of Directors (Business Wire)
Jan-26-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire) -5.11% +5.88%
09:55AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-20-26 07:00AM	Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care (Business Wire) +11.50%
Dec-29-25 09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-27-25 07:40AM	What's Driving JonesTrading's Bullish View on Mind Medicine (MindMed) Inc. (MNMD) (Insider Monkey)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly) +5.41%
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat)
Dec-18-25 07:01AM	MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire)
Dec-01-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Nov-07-25 12:03AM	Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Nov-06-25 04:01PM	MindMed Reports Q3 2025 Financial Results and Business Updates (Business Wire)
Nov-05-25 07:01AM	MindMed to Participate in Upcoming Investor Conferences (Business Wire)
04:01PM	Loading…
Nov-03-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire) -13.45%
07:01AM	Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (Business Wire)
Oct-30-25 04:01PM	MindMed to Report Q3 2025 Financial Results on November 6, 2025 (Business Wire) +6.05%
Oct-29-25 10:14PM	Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering (Business Wire)
04:01PM	Mind Medicine (MindMed) Inc. Announces Proposed Public Offering (Business Wire)
Oct-14-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire)
Sep-22-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire) +5.53%
Sep-21-25 09:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-19-25 07:00AM	New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD) (Business Wire)
Sep-08-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Sep-04-25 11:05AM	Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) (Business Wire)
Sep-02-25 03:47AM	Mind Medicine (MindMed) Inc. (MNMD)'s MM120 Earns FDA Breakthrough Status in Anxiety Treatment (Insider Monkey)
Aug-28-25 07:00AM	MindMed to Participate in September Investor Conferences (Business Wire)
Aug-12-25 03:43AM	If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Aug-11-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Aug-07-25 05:25AM	1 Reason to Buy MindMed (MNMD) (Motley Fool)
Aug-01-25 03:36AM	Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com) -7.15%
Jul-31-25 04:01PM	MindMed Reports Q2 2025 Financial Results and Business Updates (Business Wire)
Jul-25-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-24-25 07:00AM	MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025 (Business Wire)
Jul-22-25 12:00PM	All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy (Zacks)
Jul-14-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
12:01AM	This Illegal Psychedelic Is Hailed as a Revolutionary Breakthrough (WSJ)
Jun-09-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Jun-04-25 07:02AM	Why Mind Medicine Gave Investors a Powerful Buzz in May (Motley Fool)
Jun-02-25 09:55AM	Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade (Zacks)
May-28-25 07:00AM	MindMed to Participate in June Investor Conferences (Business Wire)
May-27-25 07:00AM	MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer (Business Wire)
May-21-25 11:18AM	Mind Medicine (MindMed) Inc. (MNMD): Analysts See 285% Upside Potential (Insider Monkey) -8.68%
May-20-25 05:33PM	Why Mind Medicine Stock Vaulted More Than 8% Higher Today (Motley Fool) +8.42%
May-19-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire) +6.21%
May-16-25 04:17PM	Was Jim Cramer Right About Mind Medicine (MNMD) Stock? (Insider Monkey)
May-13-25 09:55AM	Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect? (Zacks)
07:00AM	MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
May-08-25 07:00AM	MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates (Business Wire)
May-07-25 12:33PM	Mind Medicine Q1 2025 Earnings Preview (Seeking Alpha)
Apr-24-25 07:00AM	MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire) +5.24%
Apr-23-25 07:42PM	Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence (Seeking Alpha) +5.34%
Apr-21-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Apr-20-25 10:33PM	Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (Seeking Alpha)
Apr-15-25 07:00AM	MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) (Business Wire)
Mar-24-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-17-25 07:00AM	MindMed Appoints Matt Wiley as Chief Commercial Officer (Business Wire)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-06-25 07:00AM	MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates (Business Wire)
Mar-04-25 07:00AM	MindMed to Present at Leerink's Global Healthcare Conference 2025 (Business Wire)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-20-25 07:00AM	MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily) +14.34%
Feb-12-25 01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-04-25 07:00AM	MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire) +10.85%
Jan-31-25 07:20AM	Mind Medicine doses first patient in Panorama study (TipRanks)
Jan-30-25 07:00AM	MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder (Business Wire)
Jan-20-25 10:48AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-19-24 07:00AM	MindMed to Be Added to the Nasdaq Biotechnology Index (Business Wire)
Dec-16-24 07:00AM	MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) (Business Wire)
Dec-11-24 07:00AM	MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress (Business Wire)
Dec-05-24 07:00AM	MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) (Business Wire)
Dec-03-24 07:00AM	MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy (Business Wire) -7.99%
Dec-02-24 07:00AM	MindMed Announces New Employee Inducement Grants (Business Wire)
Nov-18-24 07:00AM	MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer (Business Wire) -11.86%
Nov-13-24 07:00AM	MindMed to Participate in Upcoming Investor Conferences (Business Wire)
Nov-07-24 04:01PM	MindMed Reports Third Quarter 2024 Financial Results and Business Updates (Business Wire) +11.41% +12.90%
Oct-24-24 07:00AM	MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update (Business Wire)

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Karlin Daniel	Chief Medical Officer	Mar 25 '26	Sale	18.47	8,018	148,092	413,317	Mar 26 06:43 PM
Sullivan Mark	Chief Legal Officer	Mar 25 '26	Sale	18.47	10,702	197,666	271,079	Mar 26 06:42 PM
Barrow Robert	Chief Executive Officer	Mar 25 '26	Sale	18.47	24,431	451,241	752,454	Mar 26 06:42 PM
ROBERT B BARROW	Officer	Mar 25 '26	Proposed Sale	18.47	24,431	451,241		Mar 25 05:41 PM
DANIEL ROLLINGS KARLIN	Officer	Mar 25 '26	Proposed Sale	18.47	8,018	148,092		Mar 25 05:40 PM
MARK SULLIVAN	Officer	Mar 25 '26	Proposed Sale	18.47	10,702	197,666		Mar 25 05:39 PM
Karlin Daniel	Chief Medical Officer	Dec 26 '25	Sale	13.15	5,600	73,623	425,025	Dec 29 05:00 PM
Barrow Robert	Chief Executive Officer	Dec 26 '25	Sale	13.15	25,791	339,072	778,477	Dec 29 05:00 PM
Sullivan Mark	Chief Legal Officer	Dec 26 '25	Sale	13.15	11,276	148,244	282,576	Dec 29 05:00 PM
Karlin, Dan	Officer	Dec 26 '25	Proposed Sale	13.15	5,600	73,623		Dec 29 04:15 PM
Sullivan, Mark	Officer	Dec 26 '25	Proposed Sale	13.15	11,276	148,244		Dec 29 04:15 PM
Barrow, Robert	Officer, Director	Dec 26 '25	Proposed Sale	13.15	25,791	339,072		Dec 29 04:15 PM
Sullivan Mark	Chief Legal Officer	Sep 25 '25	Sale	9.77	11,278	110,186	293,852	Sep 26 05:35 PM
Barrow Robert	Chief Executive Officer	Sep 25 '25	Sale	9.77	25,797	252,037	804,268	Sep 26 05:35 PM
Karlin Daniel	Chief Medical Officer	Sep 25 '25	Sale	9.77	7,704	75,268	430,625	Sep 26 05:34 PM
MARK SULLIVAN	Officer	Sep 25 '25	Proposed Sale	9.77	11,278	110,217		Sep 25 04:43 PM
DANIEL ROLLINGS KARLIN	Officer	Sep 25 '25	Proposed Sale	9.77	7,704	75,289		Sep 25 04:40 PM
ROBERT B BARROW	Officer	Sep 25 '25	Proposed Sale	9.77	25,797	252,106		Sep 25 04:38 PM
Sullivan Mark	Chief Legal Officer	Jun 25 '25	Sale	6.80	11,491	78,139	305,130	Jun 26 04:30 PM
Karlin Daniel	Chief Medical Officer	Jun 25 '25	Sale	6.80	7,848	53,366	438,329	Jun 26 04:30 PM
Barrow Robert	Chief Executive Officer	Jun 25 '25	Sale	6.80	26,491	180,139	830,065	Jun 26 04:30 PM
DANIEL ROLLINGS KARLIN	Officer	Jun 25 '25	Proposed Sale	6.80	7,848	53,388		Jun 25 04:09 PM
MARK SULLIVAN	Officer	Jun 25 '25	Proposed Sale	6.80	11,491	78,170		Jun 25 04:07 PM
ROBERT B BARROW	Officer	Jun 25 '25	Proposed Sale	6.80	26,491	180,210		Jun 25 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DFTX

Definium Therapeutics Inc

Upgrade your Finviz experience